创新-话题@MedSci

#创新#

1015篇内容 | 8180人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1285853, encodeId=275912858536b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, objectType=article, longId=193172, objectId=24cd1931e229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cd1931e229, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cd1931e229, moduleTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24cd1931e229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285852, encodeId=d475128585237, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=Osilodrostat：歪打正着的治疗库欣综合征的创新药物, objectType=article, longId=191440, objectId=332319144090, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=332319144090, replyNumber=0, likeNumber=49, createdTime=2020-04-06, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=332319144090, moduleTitle=Osilodrostat：歪打正着的治疗库欣综合征的创新药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=332319144090)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285851, encodeId=63691285851dd, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=FDA：审批了3款创新药获批，罕见病药物市场热潮涌动, objectType=article, longId=191439, objectId=a491191439c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a491191439c6, replyNumber=0, likeNumber=66, createdTime=2020-04-06, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a491191439c6, moduleTitle=FDA：审批了3款创新药获批，罕见病药物市场热潮涌动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a491191439c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285850, encodeId=6b7b1285850b1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=【快讯】吉凯基因完成近4亿元C轮融资，加速推动创新诊疗产品开发, objectType=article, longId=191342, objectId=b6691913423f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6691913423f, replyNumber=0, likeNumber=53, createdTime=2020-04-05, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6691913423f, moduleTitle=【快讯】吉凯基因完成近4亿元C轮融资，加速推动创新诊疗产品开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6691913423f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285849, encodeId=443f128584916, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=雷神山医院单日出院患者数创新高，一名七旬失明患者出院, objectType=article, longId=189864, objectId=ada91898648b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ada91898648b, replyNumber=0, likeNumber=76, createdTime=2020-03-13, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ada91898648b, moduleTitle=雷神山医院单日出院患者数创新高，一名七旬失明患者出院, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ada91898648b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285848, encodeId=bf381285848eb, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=流行病防范创新联盟发出呼吁，还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发, objectType=article, longId=189580, objectId=a97118958050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a97118958050, replyNumber=0, likeNumber=69, createdTime=2020-03-10, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a97118958050, moduleTitle=流行病防范创新联盟发出呼吁，还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a97118958050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285847, encodeId=0ff6128584e3e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=学术引领，数字化驱动创新营销解决方案, objectType=article, longId=189525, objectId=b53a18952507, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b53a18952507, replyNumber=0, likeNumber=92, createdTime=2020-03-08, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b53a18952507, moduleTitle=学术引领，数字化驱动创新营销解决方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b53a18952507)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285846, encodeId=3233128584648, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=日本和韩国多国新增新冠肺炎病例一日内多次创新高，WHO发警告, objectType=article, longId=188642, objectId=81b61886420b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81b61886420b, replyNumber=0, likeNumber=0, createdTime=2020-02-24, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81b61886420b, moduleTitle=日本和韩国多国新增新冠肺炎病例一日内多次创新高，WHO发警告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81b61886420b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285845, encodeId=94141285845e9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=辉瑞罕见病创新药维达全在中国获批, objectType=article, longId=188039, objectId=196c1880399d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=196c1880399d, replyNumber=0, likeNumber=72, createdTime=2020-02-15, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=196c1880399d, moduleTitle=辉瑞罕见病创新药维达全在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=196c1880399d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285844, encodeId=89c2128584442, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=重磅！默沙东将分拆为两家公司，专注研发创新生物制药, objectType=article, longId=187562, objectId=75ea18e562d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75ea18e562d0, replyNumber=0, likeNumber=86, createdTime=2020-02-07, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75ea18e562d0, moduleTitle=重磅！默沙东将分拆为两家公司，专注研发创新生物制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75ea18e562d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285843, encodeId=5f14128584388, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=重磅！精鼎医药成立法规和市场准入咨询服务专业团队，帮助客户更高效地向患者提供创新疗法, objectType=article, longId=186411, objectId=04c6186411ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c6186411ea, replyNumber=0, likeNumber=49, createdTime=2020-01-18, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c6186411ea, moduleTitle=重磅！精鼎医药成立法规和市场准入咨询服务专业团队，帮助客户更高效地向患者提供创新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c6186411ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285842, encodeId=1522128584252, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=创新不止梦圆健康，善尽责任播撒关爱 ——波士顿科学连获公益及创新领域三项殊荣, objectType=article, longId=186393, objectId=c13718639393, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13718639393, replyNumber=0, likeNumber=0, createdTime=2020-01-18, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13718639393, moduleTitle=创新不止梦圆健康，善尽责任播撒关爱 ——波士顿科学连获公益及创新领域三项殊荣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c13718639393)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285841, encodeId=56d01285841d1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=精鼎医药成立法规和市场准入咨询服务专业团队，帮助客户更高效地向患者提供创新疗法, objectType=article, longId=186369, objectId=4bf618636941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf618636941, replyNumber=0, likeNumber=67, createdTime=2020-01-18, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf618636941, moduleTitle=精鼎医药成立法规和市场准入咨询服务专业团队，帮助客户更高效地向患者提供创新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bf618636941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285840, encodeId=10c11285840db, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=三大创新！中医脉络学说指导防治微血管病变获国家科技进步一等奖, objectType=article, longId=186063, objectId=0810186063b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0810186063b9, replyNumber=0, likeNumber=77, createdTime=2020-01-12, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0810186063b9, moduleTitle=三大创新！中医脉络学说指导防治微血管病变获国家科技进步一等奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0810186063b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285839, encodeId=b319128583981, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=填补56年空白：国家药监局批准最佳治疗高钾血症创新药上市, objectType=article, longId=185846, objectId=059d185846fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=059d185846fc, replyNumber=0, likeNumber=52, createdTime=2020-01-08, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=059d185846fc, moduleTitle=填补56年空白：国家药监局批准最佳治疗高钾血症创新药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=059d185846fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285838, encodeId=716f1285838f1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=开展首例创新手术**奖60万，乐城再推制度创新, objectType=article, longId=185605, objectId=dcf0185605f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcf0185605f6, replyNumber=0, likeNumber=38, createdTime=2020-01-04, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcf0185605f6, moduleTitle=开展首例创新手术**奖60万，乐城再推制度创新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcf0185605f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285837, encodeId=d00c128583e53, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=第三届上海医改十大创新举措评选正式启动, objectType=article, longId=185562, objectId=5dc918556252, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dc918556252, replyNumber=0, likeNumber=54, createdTime=2020-01-03, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dc918556252, moduleTitle=第三届上海医改十大创新举措评选正式启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dc918556252)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285836, encodeId=e73712858365f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=55, createdTime=2020-01-03, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285835, encodeId=31cd12858357c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, objectType=article, longId=185517, objectId=d8b718551ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b718551ed7, replyNumber=0, likeNumber=61, createdTime=2020-01-02, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b718551ed7, moduleTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b718551ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1285834, encodeId=8277128583440, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=剂型创新：来那度胺透皮给药方案的可行性, objectType=article, longId=185380, objectId=bab7185380eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bab7185380eb, replyNumber=0, likeNumber=0, createdTime=2019-12-30, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bab7185380eb, moduleTitle=剂型创新：来那度胺透皮给药方案的可行性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bab7185380eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

创新

2020-05-29

lilianxiang (审核中...)

前往app查看评论内容

#创新#

AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高

2020-05-01

lilianxiang (审核中...)

前往app查看评论内容

#创新#

Osilodrostat：歪打正着的治疗库欣综合征的创新药物

2020-04-06

lilianxiang (审核中...)

前往app查看评论内容

#创新#

FDA：审批了3款创新药获批，罕见病药物市场热潮涌动

2020-04-06

lilianxiang (审核中...)

前往app查看评论内容

#创新#

【快讯】吉凯基因完成近4亿元C轮融资，加速推动创新诊疗产品开发

2020-04-05

lilianxiang (审核中...)

前往app查看评论内容

#创新#

雷神山医院单日出院患者数创新高，一名七旬失明患者出院

2020-03-13

lilianxiang (审核中...)

前往app查看评论内容

#创新#

流行病防范创新联盟发出呼吁，还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发

2020-03-10

lilianxiang (审核中...)

前往app查看评论内容

#创新#

学术引领，数字化驱动创新营销解决方案

2020-03-08

lilianxiang (审核中...)

前往app查看评论内容

#创新#

日本和韩国多国新增新冠肺炎病例一日内多次创新高，WHO发警告

2020-02-24

lilianxiang (审核中...)

前往app查看评论内容

#创新#

辉瑞罕见病创新药维达全在中国获批

2020-02-15

lilianxiang (审核中...)

前往app查看评论内容

#创新#

重磅！默沙东将分拆为两家公司，专注研发创新生物制药

2020-02-07

lilianxiang (审核中...)

前往app查看评论内容

#创新#

重磅！精鼎医药成立法规和市场准入咨询服务专业团队，帮助客户更高效地向患者提供创新疗法

2020-01-18

lilianxiang (审核中...)

前往app查看评论内容

#创新#

创新不止梦圆健康，善尽责任播撒关爱 ——波士顿科学连获公益及创新领域三项殊荣

2020-01-18

lilianxiang (审核中...)

前往app查看评论内容

#创新#

精鼎医药成立法规和市场准入咨询服务专业团队，帮助客户更高效地向患者提供创新疗法

2020-01-18

lilianxiang (审核中...)

前往app查看评论内容

#创新#

三大创新！中医脉络学说指导防治微血管病变获国家科技进步一等奖

2020-01-12

lilianxiang (审核中...)

前往app查看评论内容

#创新#

填补56年空白：国家药监局批准最佳治疗高钾血症创新药上市

2020-01-08

lilianxiang (审核中...)

前往app查看评论内容

#创新#

开展首例创新手术**奖60万，乐城再推制度创新

2020-01-04

lilianxiang (审核中...)

前往app查看评论内容

#创新#

第三届上海医改十大创新举措评选正式启动

2020-01-03

lilianxiang (审核中...)

前往app查看评论内容

#创新#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-01-03

lilianxiang (审核中...)

前往app查看评论内容

#创新#

痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点

2020-01-02

lilianxiang (审核中...)

前往app查看评论内容

#创新#

剂型创新：来那度胺透皮给药方案的可行性

2019-12-30

科室
- - 订阅+
  - 更多科室
工具
服务